Where is the Waste in Part D?
This article was originally published in RPM Report
Rooting out waste in federal health care spending is one of few points of perennial bipartisan agreement in health policy. In that spirit, a Senate Committee wants to focus on trimming the waste in the Medicare pPrescription drug program-but first they have to figure out where it is.
You may also be interested in...
Michael Loucks stepped down as acting US Attorney at the end of 2009, after a career that put him at the center of many of the largest health care fraud prosecutions in the pharmaceutical industry. We spoke to him about what happens next, for industry, for prosecutors-and for him.
Medicare/Medicaid Prosecutions: Does More Money for Fraud Activities Translate Into More Mega-Settlements?
From expanding health care coverage to collecting fees from miscreants, the lead story at HHS took a quick and sharp turn with the unveiling of the President's budget for fiscal 2011. HHS is setting high return standards for its fraud activities: $1.5 in net returns to the government for every dollar spent. Practically, that may drive HHS to press big pharma for big settlements.
FDA is planning a spring meeting to discuss next steps in a class-wide Risk Evaluation & Mitigation Strategy for opioids. The outcome will redefine the rules of commercial success in the pain class-and provide a critical case study for how FDA's new regulatory tools may reshape other sectors over time. The good news: there appear to be new opportunities amid the change. The bad: industry is definitely not driving the process.